AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms

 
• By Alex Shimmings
  
Autumn
Will CV events spook regulators? • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D